Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite

N. Barzaghi, G. Gatti, F. Crema, M. Monteleone, C. Amione, L. Leone, E. Perucca

Research output: Contribution to journalArticle

Abstract

The serum levels of carbamazepine (CBZ) and its 10,11-epoxide metabolite (CBZ-E) were determined in seven subjects after a single dose of CBZ (400 mg) in the control state and during co-administration of erythromycin (500 mg three times daily for 10 days). Erythromycin treatment was associated with a decrease in CBZ clearance and a prolongation of CBZ half-life, while CBZ-E levels were markedly reduced. These data provide evidence that erythromycin inhibits the conversion of CBZ to its epoxide metabolite.

Original languageEnglish
Pages (from-to)836-838
Number of pages3
JournalBritish Journal of Clinical Pharmacology
Volume24
Issue number6
Publication statusPublished - 1987

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite'. Together they form a unique fingerprint.

  • Cite this